LAWRENCEVILLE, N.J., March 12, 2018 (GLOBE NEWSWIRE) -- -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Michael Tardugno, Chairman, President and Chief Executive Officer, will present at the following upcoming investor conferences:
- The B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) on Friday, March 16, 2018 at 3:30 p.m. local time. The conference will be held March 15-17, 2018 at The InterContinental Hotel Hangzhou, China.
- The Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018 at 9:10 a.m. EDT. The conference will be held March 20-21, 2018 at The Westin New York Grand Central in New York City.
A live webcast of Celsion’s presentation at the Oppenheimer conference may be accessed by visiting the “News & Investors” section of Celsion’s corporate website at www.celsion.com. A replay of the webcast will also be available and archived on the site for 90 days following the presentation or until June 19, 2018.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: www.celsion.com. (CLSN-FIN)
ThermoDox® is a registered trademark of Celsion Corporation.